SAShipra Arya

Shipra Arya

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shipra Arya has a total of 208 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • AI-Driven Multimodal Risk Assessment Combining CT Imaging Biomarkers and Frailty Scores for Enhanced Mortality Prediction in Surgery Patients

    by Benjamin Liu, Arash Fereydooni, Malte Jensen, Anoushka Lakshmi, Andrea Fisher, Julie T Wu, Ramzi Dudum, Robert D Boutin, Akshay S Chaudhari, Shipra Arya

    Background: Automated frailty assessment predicts postoperative mortality, but routinely acquired CT imaging may provide complementary physiologic information. We evaluated whether AI-derived CT biomarkers improve one-year mortality prediction beyond an ICD-based Risk Analysis Index (RAI-ICD). Study Design: This retrospective cohort linked abdominopelvic CT scans obtained from 2013–2018 at a tertiary academic center to non-emergent surgery within 6 months. RAI-ICD was integrated with automated CT-derived muscle, adiposity, bone, and aortic calcification biomarkers using an XGBoost binary classification model, which we deemed the Unified Multimodal Model (UMM). The primary outcome was one-year all-cause mortality; discrimination, calibration, and decision-curve net benefit were evaluated. Results: Among 7,672 patients, one-year mortality was 12.3%; 7,638 patients were included in primary mortality models. RAI-ICD alone achieved an AUROC of 0.75 and outperformed every individual imaging biomarker. Adding all imaging biomarkers increased AUROC to 0.79 (ΔAUROC +0.04; P<0.001). UMM calibration (slope 1.00; intercept 0.01; ICI 0.01) exceeded RAI-ICD calibration (slope 0.72; intercept 0.04; ICI 0.03), particularly at higher predicted risk. At the Youden-optimal threshold, UMM PPV was 0.24, NPV 0.96, and number needed to screen was 4.1. UMM provided significantly greater net benefit overall and among Robust, Frail, and Very Frail strata. Conclusions: Integrating automated CT biomarkers with RAI-ICD improved one-year postoperative mortality prediction, high-risk calibration, and clinical net benefit compared with frailty assessment alone. External validation is required before clinical implementation.

  • Statins Use in Veterans With Peripheral Artery Disease: Insights From the PEARLS Study

    by Rohit Nathani, Cathy Nguyen, Qiang Li, Mary S. Vaughan-Sarrazin, Mohammad A. Al-Garadi, Nicole E. Minniefield-Young, Kim G. Smolderen, Shirling Tsai, Shipra Arya, Joshua A. Beckman, et al.

    BACKGROUND: Guidelines recommend high-intensity statins in patients with peripheral artery disease (PAD). We examined contemporary use of statins among real-world patients with a new diagnosis of PAD. METHODS: Within a national registry of Veterans with incident PAD, we used pharmacy claims data to determine active statin use within 1 year of PAD diagnosis. We also used laboratory data to evaluate lipid levels. Hierarchical multivariable logistic regression was used to identify variables associated with the use of any statin and high-intensity statin 1 year after PAD diagnosis and quantify variation in statin use across sites. RESULTS: Among 91 970 patients with PAD alive at 1 year, the median age was 70 years, 97.2% were men, and 18.6% were Black. At 1 year, 64 231 (69.9%) patients were on a statin, and 34 017 (37.0%) were on a high-intensity statin. Among nonstatin users, 53.4% (14 834/27 739) had not been prescribed a statin at any time in the preceding 3 years. Overall, the median low-density lipoprotein cholesterol was 81.6 mg/dL and was lower in those on high-intensity statins versus low/moderate-intensity statins versus no statins (72.2 versus 78.0 versus 100 mg/dL). Age, prior history of coronary artery disease, cerebrovascular disease, hypertension, diabetes, and current or former smoking history, obesity, and revascularization during the initial 6 months were associated with higher statin and high-intensity statin use (among statin users). At the site level, there was modest variation in statin use, especially high-intensity statins, which ranged from 20% to 54% with an overall median odds ratio of 1.39 (95% CI, 1.32–1.46). CONCLUSIONS: Nearly 70% of patients with PAD were receiving a statin within 1 year of PAD diagnosis. However, use of high-intensity statins and nonstatin lipid-lowering therapy remained suboptimal. Moreover, there was modest variation in use of statins, especially high-intensity statins, across sites, highlighting opportunities for improving guideline-concordant care in patients with PAD.

  • Open Access

    Rapid Pre-Implementation Evaluation for Multi-Specialty Surgical Trials: Informing Context-Specific Adaptations

    by Marzena Sasnal, Karleen F. Giannitrapani, Ashley H. Langston, Rana N. Doruk, Arden M. Morris, Alex H. Sox-Harris, Shipra Arya

    Objective: To demonstrate the application of the Consolidated Framework for Implementation Research (CFIR)-guided rapid qualitative methods for pre-implementation evaluation and adaptation of multi-specialty surgical trials. Background: CFIR-guided rapid qualitative methods have proven effective for pre-implementation evaluation in primary care, psychiatry, and critical care. However, their application to surgical contexts—where workflow complexity, specialty-specific practices, and time constraints present unique implementation challenges—remains unexplored. Methods: We conducted CFIR-guided formative evaluation during the pre-implementation phase of a multisite hybrid type I trial that implemented multi-disciplinary frailty optimization across 21 surgical specialty clusters at 3 Veterans Affairs Medical Centers. We employed a multi-method approach including semistructured interviews with 30 stakeholders with surgical leaders, 6 focus groups with 24 PAUSE Board members, and multi-day on-site observations at 3 intervention sites (November 2021–June 2022). Data were analyzed using CFIR-informed rapid content analysis and triangulated to ensure rigor and actionability. Results: Rapid analysis identified implementation barriers and facilitators across CFIR domains, distinguishing between core intervention functions (frailty screening and multidisciplinary optimization) and adaptable elements (screening workflows, personnel roles, communication channels). This approach enabled site- and specialty-specific pre-implementation adaptations across all 21 clusters at 3 sites while aiming to preserve intervention fidelity. Conclusions: This work provides a methodological roadmap for applying CFIR-guided rapid qualitative methods in multi-specialty surgical trials, demonstrating how systematic pre-implementation evaluation can balance fidelity with context-specific adaptation. Our approach offers practical guidance for researchers implementing complex interventions across diverse surgical specialties.

  • Open Access

    Cumulative Metabolic Exposure to Hyperglycemia and Risk of Cardiovascular and Limb Events in Peripheral Artery Disease

    by Feroz James, Qiang Li, Medha Somisetty, Cathy Nguyen, Mary S Vaughan-Sarrazin, Brian Lund, Shirling Tsai, Kim G. Smolderen, Richard M Hoffman, Shipra Arya, et al.

    Background: Although diabetes is a potent risk factor for the development of peripheral artery disease (PAD), the effect of cumulative metabolic exposure to hyperglycemia on risk of cardiovascular or limb events in patients with PAD remains unclear. Methods: The Peripheral Artery Disease: Long-term Survival (PEARLS) is a longitudinal registry of Veterans with newly diagnosed PAD identified using a natural language processing approach. Included patients had ankle brachial index ≤0.9 or toe brachial index ≤0.7, and no history of lower extremity revascularization or major amputation. Among patients with diabetes in this cohort, we assessed cumulative exposure to hyperglycema based on a 24-month rolling average of hemoglobin (Hgb) A1c values, categorized as ≤7%, >7% to ≤8%, and >8%. Multivariable Cox regression models evaluated the association between categories of HgbA1c, modeled as a time-varying exposure, and risk of cardiovascular (CV: myocardial infarction or stroke) and limb (chronic limb threatening ischemia [CLTI] or major amputation) events. Results: Among 45,109 patients with new diagnosis of PAD and pre-existing diabetes, the mean HgbA1c at baseline was 7.5%, with nearly one-third (30.4%) having HgbA1c >8%. The mean age was 70.4 years, 19.8% were Black and 4% were Hispanic. Patients with baseline HgbA1c >8% were younger and compared to those with HgbA1c ≤7%, more likely to have coronary disease, kidney disease, and obesity. Over a median follow up of 4.2 years, 8,306 (18.4%) patients experienced a CV event, and 8,199 (18.2%) experienced a limb event. The adjusted association between HgbA1c and hazard of CV events was 12% higher in patients exposed to HgbA1c >7% to ≤8% (HR 1.12; 95%CI: 1.05-1.18) and 38% higher in those exposed to HgbA1c >8% (HR 1.38; 95%CI: 1.30-1.46), compared to HgbA1c 7% to ≤8% (HR 1.20; 95%CI: 1.13-1.28) and HgbA1c >8% (HR 1.60; 95%CI: 1.51-1.70), respectively when compared to HgbA1c ≤7%. These findings were consistent in subgroups based on age and severity of PAD. Conclusions: Among diabetic patients with PAD, cumulatiave metabolic exposure to hyperglycemia is associated with a markedly increased risk of clinical events, especially limb events.

  • Open Access

    Balancing Days at Home and Major Adverse Limb Events After Surgical Versus Endovascular Lower‐Extremity Revascularization in Chronic Kidney Disease

    by Tara I. Chang, Gomathy Parvathinathan, Sai Liu, Jun Young Lee, Ali Etemadi, Shipra Arya, Margaret R. Stedman

    Background: The risk–benefit trade‐offs after lower‐extremity revascularization among older patients with chronic kidney disease remain unclear. We compared how surgical versus endovascular lower‐extremity revascularization associates with clinical outcomes that may be valued differently by patients. Methods: We selected adults aged ≥66 years with chronic kidney disease who underwent lower‐extremity revascularization from January 1, 2008, to December 31, 2017, with ≥12 months Medicare Parts A and B before the procedure. The primary outcome was days at home at 30, 180, and 365 days after revascularization. The secondary outcome was major adverse limb events (ie, lower‐extremity revascularization or major amputation). We report outcomes as the difference in survived days at home and days lost due to major adverse limb events by restricted mean time lost. Results: Among 87 446 patients, 15.3% underwent surgical and 84.7% underwent endovascular revascularization. Surgical revascularization was associated with fewer days at home at 30 days (difference, −8.4 [95% CI, −8.6 to −8.2]), 180 days (difference, −21.2 [95% CI, −22.1 to −20.4]) and 365 days (difference, −31.9 [95% CI, −33.5 to −30.6]) compared with endovascular. Surgical revascularization was associated with fewer days lost to major adverse limb events at 180 days (difference, −6.9 [95% CI, −7.6 to −5.8]) and at 365 days (difference, −17.3 [95% CI, −19.3 to −14.7]). Conclusions: In this study of older patients with chronic kidney disease, surgical lower‐extremity revascularization was associated with fewer survived days at home, but also with fewer days lost to major adverse limb events compared with an endovascular approach. Considering different risk–benefit profiles when planning for lower‐extremity revascularization is essential to facilitate shared decision making.


  • Peripheral Vascular Calcification

    by Sujin Lee, Jenny Woo, Yabing Chen, Shipra Arya, Matthew Allison

    Peripheral artery disease commonly refers to diffuse atherothrombotic disease of the arteries supplying the legs. Peripheral artery disease has been relatively understudied and has not been subject to the same intensive scrutiny and research that characterizes coronary artery disease. Moreover, the diagnosis of peripheral artery disease can be complicated by the presence of arterial calcification. Here, we provide a brief report on the current understanding of peripheral vascular calcification to include the following sections: basic mechanisms, anatomic distribution of arterial calcification, manifestations, risk factors, measurement of peripheral calcification, nonsurgical treatments, and surgical interventions.


  • Open Access

    Navigating the Complexity of Lung Cancer Surveillance Practices: Qualitative Pilot Study on Provider Perspectives

    by Jenny M Woo, Sydney Conover, Caroline Gray, Shipra Arya, Julie T Wu

    Background: Surveillance is noted to be an important part of survivorship to detect recurrence and/or second primary lung cancer (SPLC) at a curable stage. However, current surveillance guidelines remain controversial, and the factors providers consider in clinical decision-making are neither well-defined nor consistently applied. Objective: In order to inform the qualitative protocol for a larger national study, this pilot study aimed to understand the factors that influence lung cancer surveillance and how providers view risk stratification as a potential tool to inform surveillance practices. Methods: Semistructured interviews were conducted between October 2023 and July 2024 with purposively sampled providers involved in treating and surveilling patients with lung cancer from the US-based Palo Alto Veterans Affairs Medical Center and Stanford Medicine and its affiliate clinics. Providers were recruited through both email outreach and in-person invitations. Interviews were transcribed by an external transcription service and analyzed through a qualitative inductive content analysis approach to identify themes. Results: In total, 11 physicians and 2 advanced practice providers (N=13) participated in interviews. The majority were from medical specialties (n=8, 61.5%), and the average number of years of practice as a provider was 9 years. A total of 3 themes were identified that describe the clinicians’ sentiments about current surveillance practices and how a risk stratification tool could be used in screening for recurrence and/or SPLC. Clinicians consider a variety of clinical and nonclinical factors (category 1: factors that influence clinical decision making) and highlighted limits of a risk stratification tool, including concerns about generalizability, accuracy, and validity (category 2: sentiments toward a hypothetical risk stratification tool). Finally, concerns were raised about how delivering risk stratification data might impact patient anxiety, misinterpretation, and adherence to surveillance plans (category 3: delivery of risk stratification data to patients). Conclusions: This qualitative analysis highlights the complexity of lung cancer surveillance decision-making and provider concerns about tool accuracy and delivery. While risk stratification tools may support surveillance decisions, their further development must address data quality, accuracy across diverse clinical and nonclinical risk factors, and effective patient-level data delivery. Doing so will facilitate the practical implementation of risk stratification tools to improve surveillance of SPLC and recurrence.

  • Open Access

    Blood Pressure and Risk of Clinical Events in Peripheral Artery Disease

    by Saket Girotra, Mary Vaughan-Sarrazin, James A. de Lemos, Paul S. Chan, Ajay K. Gupta, Qiang Li, Cathy Nguyen, Brian C. Lund, Rohit Nathani, Richard M. Hoffman, et al.

    Background Current guidelines recommend a blood pressure (BP) goal ≤130/80 mm Hg in peripheral artery disease (PAD) even though few PAD patients were enrolled in the landmark BP-lowering trials. Moreover, intensive BP control can worsen limb perfusion and none of the trials adjudicated limb events. Methods Using data from a longitudinal registry of US Veterans, we identified 91,296 patients (>2.7 million BP values) with a new diagnosis of PAD during 2015-2020. Multivariable Cox regression models evaluated the association between longitudinal BP values (time-varying exposure) and risk of cardiovascular (CV: myocardial infarction, stroke) and limb (chronic limb threatening ischemia, major amputation) events. Results Mean age was 70.5 years, 97.3% were men and 18.5% were Black race. At baseline, the mean (SD) systolic BP was 133 (19) mm Hg and diastolic BP was 73 (11) mm Hg. Over a median 4.1 years, the incidence of CV and limb events was 4.6 per-100 patient-years and 5.0 per 100-patient-years, respectively. In adjusted Cox models, systolic BP ≥140 mm Hg was strongly associated with higher risk of CV events with increasing risk across BP categories (130-139 mm Hg [reference]; 140-149 mm Hg: hazard ratio [HR]: 1.28 [95%CI: 1.16-1.41]; 150-159 mm Hg: HR 1.54 [1.39-1.72]; >160 mm Hg: 2.22 [2.02-2.44]). However, there was no association between systolic BP below 130 mm Hg and risk of CV events. In contrast, the association between systolic BP and limb events was U-shaped with the highest hazard of limb events at both low (Conclusion Current recommendations for BP goal in PAD patients are associated with optimizing risk of CV events but associated with a higher risk of limb events. Our findings highlight the need to better define BP goals for PAD patients, especially those at an increased risk of limb events.

  • Preimplementation expectations and perceptions of a preoperative frailty screening and optimization intervention: A qualitative analysis

    by Zaria N. Cosby, Ashley H. Langston, Rana N. Doruk, Marzena Sasnal, Karleen F. Giannitrapani, Alex H.S. Harris, Arden M. Morris, Shipra Arya